The US FDA Approves Gilead’s Vemlidy 25mg Tablets for the Treatment of Chronic Hepatitis B Virus (HBV) Infection in Pediatric Patients
Read More: Gilead
The US FDA Approves AstraZeneca’s Voydeya as an Add-on Therapy to Treat Extravascular Haemolysis in PNH Patients
Read More: AstraZeneca
The US FDA Grants ODD to Biostar Pharma’s Utidelone Injectable to Treat Breast Cancer Brain Metastasis
Read More: Biostar Pharma
Fractyl Health’s IDE for Revita Receives the US FDA Approval for Conducting Remain-1 Study to Treat Obesity
Read More: Fractyl Health
HUTCHMED and Innovent Report the NMPA’s NDA Acceptance for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer
Read More: HUTCHMED
The US FDA Accepts AstraZeneca and Daiichi Sankyo’s BLA of Datopotamab Deruxtecan (Dato-DXd) to Treat Breast Cancer
Read More: AstraZeneca and Daiichi Sankyo’s
The EMA Accepts Rocket Pharmaceuticals’ MAA of RP-L102 for Treating Fanconi Anemia
Read More: Rocket Pharmaceuticals
The EC Expands Approval of BMS’ Reblozyl as a 1L Treatment of Transfusion-Dependent Anemia Due to Myelodysplastic Syndromes
Read More: BMS
Vanda Pharmaceuticals’ Fanapt Gains the US FDA’s Approval to Treat Bipolar I Disorder
Read More: Vanda Pharmaceuticals
The US FDA Accepts UCB’s sBLA of Bimzelx (bimekizumab-bkzx) for the Treatment of Hidradenitis Suppurativa
Read More: UCB
Incyte and China Medical System Collaborate on Povorcitinib for Autoimmune and Inflammatory Dermatologic Indications
Read More: Incyte and China Medical System
Ipsen and Sutro Biopharma Join Forces on STRO-003 for Treating Solid Tumors
Read More: Ipsen and Sutro Biopharma
MaxCyte Partners with Be Biopharma to Develop Engineered B Cell Medicines (BCMs)
Read More: MaxCyte
Caris Life Sciences and Merck KGaA Join Forces to Discover and Develop ADCs for Cancer Treatment
Read More: Caris Life sciences and Merck
MiNA Therapeutics and Nippon Shinyaku Partner on RNAa Therapeutics for Rare Neurodegenerative Diseases
Read More: MiNA Therapeutics and Nippon Shinyaku
For an Aggregate of $1.8B, Genmab to Acquire ProfoundBio for Enhancing its Oncology Portfolio
Read More: Genmab
ARCA Biopharma Merges with Oruka Therapeutics to Develop Biologics for Chronic Skin Diseases
Read More: ARCA & Oruka
For an Aggregate of ~$13.1B, Johnson & Johnson to Acquire Shockwave Medical
Read More: Johnson & Johnson & Shockwave Medical
PassPort Technologies Reveals P-I Study Results of Zolmitriptan Transdermal Microporation System to Treat Acute Migraine
Read More: PassPort Technologies
The US FDA Clears Abbott’s Whole Blood Rapid Test for Evaluating Patients with Suspected Concussion
Read More: Abbott
The US FDA Approves Abbott’s Triclip Transcatheter Edge-To-Edge Repair System to Treat Tricuspid Regurgitation
Read More: Abbott
The US FDA Grants 510(k) Clearance to AngioDynamics’ AlphaVac F18⁸⁵ System for the Treatment of Pulmonary Embolism
Read More:Angiodynamics
BMS Reveals the P-III (YELLOWSTONE) Trial Results of Zeposia for Treating Moderate to Severe Active Crohn’s Disease
Read More: BMS
EnteroBiotix Reports the Initiation of P-II Study Evaluating EBX-102-02 to Treat Irritable Bowel Syndrome (IBS)
Read More: EnteroBiotix
Merck and Daiichi Sankyo Dose First Patient with Raludotatug Deruxtecan in P-II/III (REJOICE-Ovarian01) Study to Treat Ovarian Cancer
Read More: Merck & Daiichi Sankyo
SpliSense Receives the US FDA’s Clearance for SPL84 P-II Clinical Evaluation to Treat Cystic Fibrosis
Read More: SpliSense
Neurocrine Biosciences Reports First Patient Dosing with NBI-1070770 Under the P-II Study to Treat Major Depressive Disorder
Read More: Neurocrine Bioscience
Merck Reports the Commencement of MK-1084’s P-III Study in Combination with Keytruda for Treating Metastatic Non-Small Cell Lung Cancer
Read More: Merck
AstraZeneca Reports the P-III Study Results of Imfinzi for the Treatment of Small Cell Lung Cancer
Read More: AstraZeneca
Teva Pharmaceuticals Partners with mAbxience to Develop Biosimilar Candidates for Treating Oncology Indications
Read More: Teva Pharmaceuticals
Related Post:- PharmaShots Weekly Snapshots (March 26 – March 29, 2024)
